ArticleInternational journal of clinical and experimental pathology2018
CD163
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 citations in OpenAlex.
- Immune cell clustering identifies a CD163⁺/CSF1R⁺ macrophage and neutrophil-enriched phenotype with distinct biological signatures and poor prognosis in angiosarcoma.Oncoimmunology · 2026Article
- Spindle Cell Sarcoma of the Abdominal Aorta Following Endovascular Aneurysm Repair in a Kidney Transplant Recipient.Case reports in transplantation · 2026Article
- POEMS syndrome with undetectable M-protein: a case report and literature review.Diagnostic pathology · 2024Review
- Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis.Annual review of physiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcoma of soft tissue is a group of aggressive malignancies with high mortality. However, molecular pathogenesis and therapeutic targets of angiosarcoma remain to be established. We explored the influence of M2-polarized tumor-associated macrophages (TAMs) on the formation of angiosarcoma. CD163
Indexed as
Identifiers
31938319PMC6958200W3015034163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.